Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides technologies and products used in the manufacturing of biologic drugs.
Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...